Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS

Phase 1

Completed

• Conditions: Amyotrophic Lateral Sclerosis
• Interventions: Biological: intrathecal injection

• Registration Number: NCT01771640
• Lead Sponsor: Royan Institute

Brief Summary

ALS is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and difficulty breathing (dyspnea). ALS is the most common of the five motor neuron diseases.Riluzole (Rilutek) is the only treatment that has been found to improve survival but only to a modest extent. It lengthens survival by several months, and may have a greater survival benefit for those with a bulbar onset. It also extends the time before a person needs ventilation support.Stem cell transplantation is a new hopeful way to improve the patients conditions and reduce the period of disabilities.

Detailed Description

In this study our purpose is to evaluate the safety of intraventricular injection of bone marrow derived mesenchymal stem cell.the patients who are eligible,underwent bone marrow aspiration.after cell separation and preparation,the patients underwent mesenchymal stem cell intraventricular injection by stereotaxis.after injection he will be under observed in ICU to monitor the adverse events(allergic and neurological side effects).patients are followed 1th,3th ,6th and 12 months after injection and each time these parameters are checked:ALS-FRS,EMG-NCV,FVC,side effect check list.

Study Timeline

• Status Verified: 2012-05
• Study First Submitted: 2013-01-16
• Study First Submitted QC: 2013-01-16
• Study First Posted: 2013-01-18
• Study Start: 2013-08
• Primary Completion: 2014-10
• Study Completion: 2014-12
• Last Update Submitted: 2018-03-06
• Last Update Posted: 2018-03-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• Age:18-65
• both gender
• duration of disease<2 years
• FVC>40% ALS-FRS>26

Read More

Exclusion Criteria

• neurological and psychiatric concomitant disease
• concomitant systemic disease
• treatment with corticosteroid,Ig,immunosuppressive during 12 months.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
stem cell reciepient	intrathecal injection	The patients with ALS that underwent mesenchymal stem cell transplantation

Primary Outcome Measures

Name	Time	Method
Unconscious	48hours	Evaluation the rate of unconsciousness during 48hour after transplantation
Fever	48hours	Evaluation the rate of fever during 48hour after transplantation
Vomiting	48hours	Evaluation the nausea and vomiting 48hours after transplantation.

Secondary Outcome Measures

Name	Time	Method
ALS-FRS	6months	Evaluation the improvement of ALS-FRS during 6months after transplantation.
FVC	6months	Evaluation the improvement of FVC by spirometry during 6months after transplantation

Trial Locations

Locations (1)

Royan Institute; 🇮🇷 Tehran, Iran, Islamic Republic of